Cubist Systematic Strategies LLC Has $697,000 Position in Mesoblast Limited (NASDAQ:MESO)

Cubist Systematic Strategies LLC increased its position in Mesoblast Limited (NASDAQ:MESO) by 241.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,191 shares of the company’s stock after buying an additional 24,870 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Mesoblast were worth $697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Strategic Financial Concepts LLC acquired a new position in shares of Mesoblast in the fourth quarter valued at approximately $2,744,000. Quadrant Capital Group LLC increased its stake in shares of Mesoblast by 41.1% in the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company’s stock valued at $129,000 after buying an additional 1,891 shares during the period. LPL Financial LLC increased its position in Mesoblast by 7.7% during the 4th quarter. LPL Financial LLC now owns 38,882 shares of the company’s stock valued at $770,000 after purchasing an additional 2,795 shares during the period. Oaktree Fund Advisors LLC acquired a new stake in Mesoblast during the 4th quarter valued at approximately $949,000. Finally, Clayton Financial Group LLC acquired a new stake in Mesoblast during the 4th quarter valued at approximately $275,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on MESO. Cantor Fitzgerald raised shares of Mesoblast to a “strong-buy” rating in a research report on Monday, March 31st. Piper Sandler reissued an “overweight” rating and set a $24.00 target price (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Mesoblast currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Trading Up 3.6%

Shares of MESO stock opened at $11.95 on Friday. Mesoblast Limited has a 52 week low of $5.78 and a 52 week high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm has a 50 day moving average of $11.81 and a 200-day moving average of $13.79.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.